Stroke

Two major organizations have released a new statement outlining topics of research related to VTE in need of further research going forward.

An associate professor of medicine at Yale School of Medicine discusses the results of a study aimed at assessing the potential pathophysiology of COVID-19-associated blood clots.

New data from Mount Sinai Hospital suggests anticoagulant use could improve survival rates among patients hospitalized with COVID-19.

The AAN has released an update to their 2016 practice advisory—changing their stance on PFO closure to reduce risk of second stroke.

The Professor of Medicine at Duke University School of Medicine discusses prescribing DOACs and his opinion on a recent meta-analysis in the Annals of Internal Medicine.

Research from investigators at Brigham and Women's Hospital and Sinai Health is shedding new light on the differences in safety and efficacy between the 2 DOACs.

Analysis of more than 13k patients from Taiwan found a vegetarian diet was linked to a lower risk of incident stroke events later in life.

A fourth-year medical student discusses strategies for anticoagulation reversal in intensive care units from a presentation during the 49th Annual Critical Care Congress in Orlando.

A secondary analysis of patients with prior stroke, TIA, or thromboembolism from AUGUSTUS is revealing more about the use of apixaban in patients with AFib.

A study presented today at the 2020 International Stroke Conference in Los Angeles finds that the long-term use of low-dose aspirin in ischemic stroke patients who have a glucose-6-phosphate dehydrogenase (G6PD) deficiency, may have higher risks of moderate-to-severe bleeding and all-cause death.

The chances of having an acute ischemic stroke (AIS) due to atrial fibrillation 14 days post stroke or transient ischemic attack (TIA) is high, according to a study presented today during the start of the 2020 International Stroke Conference being held in Los Angeles this week.

Discussing the key differences in the results of ISCHEMIA and ISCHEMIA-CKD, which examined whether the use of invasive or conservative strategies was more effective for patients with ischemic heart disease.

In a presentation at AHA, T. Jared Bunch, MD, discusses how early detection of AF could yield positive results down the line for patients.

Results of the TWILIGHT-ACS study revealed use of ticagrelor plus aspirin following coronary intervention in patients with acute coronary syndrome increased the risk of major bleeding.

A new analysis of the Paris Prospective Study III has revealed physical activity at work and physical activity from sport have very different effects on cardiovascular health.

A recent study has found the long-term risk of developing thromboembolism with postoperative atrial fibrillation was similar to that of nonsurgical, nonvalvular atrial fibrillation.

A Q&A with Brett Carroll, MD, director of Vascular Medicine at Beth Israel Deaconess Medical Center, as he discusses stroke management, DOACs, and warfarin.

Investigators from the University of Duke School of Medicine compared results of the PROSPER Study and found results supporting the use of DOACs over warfarin in older patients following ischemic stroke.

An analysis that included data on more than 50,000 patients found that multiple metrics of warfarin control were individuals associated with subsequent bleeding.

Dalteparin sodium injection was shown to result in VTE resolution in a majority of treated patients from a clinical trial.

Patients treated with dabigatran following myocardial injury after noncardiac surgery were 20% less likely to die of a cardiovascular cause.

The Computed Tomography Angiography device from iSchemaView gives physicians quick, and diverse, options to analyze stroke patient candidates.

A retrospective analysis of Swedish cohort data indicates that warfarin is effective enough to remain a valid alternative to novel oral anticoagulants in patients with atrial fibrillation.

A new analysis of serious bleeds among patients who use the blood thinner warfarin to treat atrial fibrillation found that consideration of anticoagulation quality would improve the accuracy of 3 bleeding risk scores.

Analysis of cardiovascular registry data comparing components of the CHA2DS2-VASc score and oral anticoagulant use also found that women and patients with vascular disease were less likely than other patients with atrial fibrillation to be prescribed anticoagulation that is now indicated by standard guidelines.

Andexanet alfa is designed to reverse the anticoagulant activity of both direct and indirect Factor Xa inhibitors.

ORLANDO -- Barely half of patients with atrial fibrillation who were prescribed rivaroxaban (Xarelto) to prevent stroke remained on the treatment after 2 years, but their adherence was still better than Afib patients on warfarin or dabigatran (Pradaxa), researchers said here.

An investigational drug called andexanet alfa that can reverse the anticoagulant effects of FXa inhibitors met all primary and secondary efficacy endpoints, researchers said in a late-breaking clinical trial report at the AHA meeting in Orlando.

Intravenous administration of tissue plasminogen activator (tPA) appears safe in selected patients who were already on novel oral anticoagulants (NOACs) a team reported at the American Heart Association Annual Scientitific Session in Orlando, FL.

There are many anti-thrombotics available. An industry study showed apixaban had the best record of dissolving clots without causing major bleedign.